News

The Dartmouth-Hitchcock health system is starting a three-year nationwide study of the quality of care that multiple sclerosis patients receive. It will focus on geographic differences in care and quality improvement. The project’s name is the Multiple Sclerosis Continuous Quality Improvement Collaborative study. Its goal is to improve care by sharing…

A recent pop-up cafe in Dublin allowed customers to experience what it’s like to live with multiple sclerosis (MS) to highlight the urgent need for improved access to care and treatment for MS patients in Ireland. MSunderstood Café gave customers a small taste of the challenges and symptoms MS…

When and how to best use disease-modifying therapies (DMTs) in multiple sclerosis depends on key treatment decisions that, partly because the number of DMTs available, can be as challenging for clinicians as they are for patients. DMTs and their optimal use will be covered in the closing lecture of the…

A new company called Pipeline Therapeutics will focus on developing next-generation therapies for regenerating the key nerve-protection process that is damaged in multiple sclerosis. Roche, Inception Sciences, and the venture capital firm Versant Ventures laid the groundwork for Pipeline by establishing a partnership in June 2014 that formed the…

Online training in  meditation based on mindfulness can improve the quality of life for multiple sclerosis (MS) patients while easing depression, anxiety, and sleep problems, a study conducted in Italy reports. These findings add to the growing body of evidence that interventions able…

In the first year after being diagnosed with multiple sclerosis (MS) in 1997, Ann Borsellino basically withdrew from life, rarely even leaving her bedroom. Knowing little about the disease, she assumed its relapses would soon rob her of any control over her body. They didn’t, and now Borsellino is involved with…

A Phase 3 trial testing an oral once-a-day therapy — ADS-5102 (amantadine) extended release capsules — in multiple sclerosis (MS) patients with walking difficulties has enrolled its first participant, Adamas Pharmaceuticals announced. The multi-center, double-blind study (NCT03436199) will assess ADS-5102 in about 570 such patients at five sites…

A lot of people with multiple sclerosis take disease-modifying therapies to reduce the inflammation associated with the disease — but in many patients, the treatments’ effectiveness wanes at a certain points. When that occurs, the question is whether to stop taking these treatments, known as DMTs. A study reports that patients’…

An interactive, psychotherapy-based online program known as Elevida can effectively reduce fatigue in patients with multiple sclerosis (MS), results of a clinical study show. In their study, “Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis,” published in the Journal of Neurology,…

A new project aimed at boosting the development of new therapies for multiple sclerosis (MS) and other demyelinating diseases recently won $1.7 million in funding from the National Institutes of Health (NIH). In the five-year study, a research team at the University at Buffalo (part of the State University…

A certain type of pain-relief treatment during childbirth does not increase the risk that women with multiple sclerosis will have relapses after delivering, a European study reports. The research involved treatments called neuraxial analgesia, so the scientists titled their study “Neuraxial analgesia is not associated with an increased risk of…

Multiple sclerosis patients are among those with debilitating diseases who are most satisfied with their healthcare, two surveys indicate. Others who are satisfied include people with amyotrophic lateral sclerosis and Parkinson’s, according to the questionnaire-based PatientsLikeMe research. In contrast, people with fibromyalgia, post-traumatic stress disorder (PTSD) and major depressive disorder…

The U.S. Food and Drug Administration (FDA) recently cleared the myBioness mobile app, designed by Bioness, to be used with the L300 Go System to improve muscle strength in patients with multiple sclerosis (MS) or other conditions that affect walking. The L300 Go System is approved to help…

Ocrevus (ocrelizumab) was more effective than Rebif (interferon beta-1a) at preventing relapsing multiple sclerosis activity, according to an analysis that covered two Phase 3 clinical trials. The comparison dealt with the therapies’ ability to generate and maintain a condition known as no evidence of disease activity,…

The laboratory-generated antibody GNbAC1 continued to limit brain shrinkage a year after relapsing-remitting multiple sclerosis patients began receiving it, its developers announced. GeNeuro and Servier were reporting on the 12-month results of a Phase 2b clinical trial. GNbAC1 is a monoclonal antibody that destroys a harmful retroviral protein called pHERV-W which scientists have…

Topline results of an exploratory Phase 2 clinical trial revealed that Flex Pharma‘s treatment candidate FLX-787 improves muscle cramps, spasms and muscle stiffness in patients with multiple sclerosis (MS). The double-blinded trial, conducted in Australia, evaluated an oral dose of 19 mg FLX-787, taken twice daily in liquid…

A year after U.S. regulators approved Genentech’s Ocrevus (ocrelizumab) as the first treatment for both the relapsing and progressive forms of multiple sclerosis, a prominent neurologist involved in the Phase 3 clinical trials that led to its authorization says it has been beneficial for some MS patients. But it’s simply…

Cigarette smoking increases the relapse rate in patients with relapsing-remitting multiple sclerosis who are being treated with interferon-beta, a study suggests. The findings suggest that RRMS patients who smoke may have fewer relapses if they quit. An article on the results, “Smoking affects the interferon beta treatment response in multiple sclerosis,” appeared in the journal Neurology. A number of studies have looked at the link between environmental and lifestyle factors and the risk of developing MS. These factors include how much sunlight and vitamin D patients get and whether they have an Epstein-Barr virus infection. Cigarette smoking is a well-documented risk factor in MS, but most of the studies on it have focused on the link between smoking and MS, or the link between smoking and the  disease's progression. “Studies that addressed the relationship between smoking and disease activity in RRMS are rarer,” the researchers wrote. The team decided to investigate whether smoking during interferon-beta treatment would affect relapse rates. Previous research had set the stage for the study by showing a link between smoking and gene mutations that make people more susceptible to developing MS. The mutations were in the HLA and NAT1 genes. The team looked at DNA from 834 RRMS patients in the Danish Multiple Sclerosis Biobank who were treated with interferon-beta. Well-known brand names of the treatment include Rebif, Avonex, and Plegridy. There are also other brand names and biosimilar drugs. Researchers also looked at patients’ medical records two years before they started on interferon-beta. Before making any conclusions on possible links between smoking and patients' relapse rate, the team adjusted for patients’ sex, age at the start of treatment, and number of relapses in the two years before treatment began. Their key conclusion was that smoking increased by more than a quarter the number of relapses in patients on interferon-beta therapy. “Each pack of cigarettes more per day during IFN-β [interferon-beta] treatment increased the number of relapses by 27%,” the team wrote. The researchers found no association among smoking, relapses, and mutations of the HLA or NAT1 genes. “Our results confirm that lifestyle factors are important in MS, suggesting that smoking cessation may be associated with a reduction in disease activity,” they wrote. “Although not formally proving that smoking cessation will decrease disease activity in RRMS, the results should encourage physicians to inform patients with MS about the harmful effect of smoking and increase focus on smoking cessation,” they observed.

Siponimod (BAF312) reduces the risk of disability progression in patients with secondary progressive multiple sclerosis (SPMS), a Phase 3 clinical trial shows. An article about the Novartis therapy’s trial results appeared in the journal The Lancet. The title is “Siponimod versus placebo in secondary progressive multiple sclerosis…

The United Spinal Association will hold a webinar this week to seek ideas for making air travel better for wheelchair users, including multiple sclerosis patients. One focus of the event will be the problems wheelchair users have encountered at airports. Another will be bills in the U.S. House and Senate…

Depression, anxiety and other mood disorders contribute to physical disability in women with multiples sclerosis, according to a Canadian study that confirmed the results of previous research. The article the team wrote, “Psychiatric comorbidity is associated with disability progression in multiple sclerosis,” appeared in the journal…

Emerald Health‘s investigational cannabidiol-derived EHP-101 reduces neuroinflammation, the risk of loss of myelin, and nerve cell damage in two mouse models of multiple sclerosis (MS), a new study shows. These results support the potential therapeutic benefits of EHP-101 for MS, and Emerald Health Pharmaceuticals expects to launch a human…

The Consortium of Multiple Sclerosis Centers (CMSC) is partnering with a number of organizations during Multiple Sclerosis Awareness Month in March to provide education, research and services to the MS community. CMSC is a non-profit organization that provides educational programs and resources to MS professionals, healthcare providers, researchers and the…

Medical cannabis is a safe and effective treatment for pain relief and should be integrated into current clinical practice, according to a new evidence overview. Benefits also include reduced spasticity in multiple sclerosis patients. The overview, titled “Special Issue: Cannabis in Medicine,” was published in the…

Symbiotix Biotherapies has gained access to Harvard University material that could help it develop treatments for autoimmune and inflammatory diseases like multiple sclerosis and inflammatory bowel diseases. It obtained access to the intellectual property, much of which deals with gut bacteria, under a licensing agreement with Harvard. Intellectual property typically includes…

Blood stem cell transplants lead to significant improvements in relapsing-remitting multiple sclerosis patients’ disability, a Phase 3 clinical trial shows. The 110 patients who took part in the MIST study (NCT00273364) were having relapses after receiving standard therapies such as beta interferon, Copaxone (glatiramer acetate), Novantrone (mitoxantrone), Tysabri (natalizumab), Gilenya (fingolimod),…

The American Brain Foundation has started a crowdfunding campaign to support research that could lead to treatments for multiple sclerosis and other autoimmune and inflammatory diseases. Foundation officials said the funds will help facilitate the work of Steffen Jung, head of the immunology department at the Weizmann Institute of Science in Israel.

Treatment with umbilical cord stem cells was found to be safe and leads to sustained improvements in disability and brain lesions of multiple sclerosis (MS) patients, according to a clinical trial. The study, “Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis,” was…

More studies are showing that medical cannabis can alleviate symptoms of multiple sclerosis (MS), according to a company that helps patients, doctors and others understand genetic conditions better. The observation came in GeneFo’s 2018 Guide to Clinical Effects of Medical Cannabis. Some research has suggested that cannabis strains containing…

Physical and psychiatric comorbidities in multiple sclerosis (MS) patients are associated with an increased risk of experiencing more pain — namely pain intensity and pain affect. The research to support that finding, “Psychiatric and physical comorbidities and pain in patients with multiple sclerosis,” was published in the Journal of Pain…